Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.

Trial Details

NCT ID

NCT06690827

Phase

PHASE1

Sponsor

Chongqing Precision Biotech Co., Ltd

Status

RECRUITING

Cancer Type

Leukemia

Interventions

Anti-CD123 CAR NK cells

Locations (sample)

Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

Patients of any gender, aged between 18 and 75 years (inclusive);
Positive expression of CD123 on tumor cells detected by flow cytometry;
Patients with a confirmed diagnosis of CD123-positive relapsed/refractory AML or BPDCN:
(1) For AML patients：

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →